Dr. Paul Richardson, Dana-Farber Cancer Institute, presents an abstract on Isatuximab plus Pomalidomide/Low-Dose Dexamethasone versus Pomalidomide/Low-Dose Dexamethasone in patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM).

Background:

Based on the primary analysis of the Phase 3 ICARIA-MM study (NCT02990338), isatuximab (Isa), an anti-CD38 monoclonal antibody, is approved in combination with pomalidomide and dexamethasone (Pd) in several countries for patients with relapsed and refractory multiple myeloma (RRMM) who have received at least 2 prior treatments, including lenalidomide and a proteasome inhibitor. Here, we describe updated, longer-term efficacy data following subsequent therapy.

Conclusions:

This analysis demonstrates that the majority of patients with RRMM require multiple lines of subsequent therapy, even after receiving a triplet combination that includes a monoclonal antibody. The immediate use of an anti-CD38 monoclonal antibody with currently available combinations appears to be less effective in the Isa-Pd arm. The more frequent use of subsequent daratumumab in Pd (59.7%) compared with Isa-Pd (22.5%) may have affected the power to detect statistically significant OS given the sample size, as well as reflecting the efficacy of this approach in the management of RRMM.

Authors:

Paul G. Richardson, MD, Aurore Perrot, MD, PhD, Jesús San-Miguel, MD, PhD, Meral Beksac, MD, Ivan Spicka, MD, Prof, PhD, Xavier Leleu, MD, PhD, Fredrik Schjesvold, MD, PhD, Philippe Moreau, MD, Meletios A. Dimopoulos, MD, Jeffrey SY Huang, MD, PhD, Jiri Minarik, MD, Michele Cavo, MD, H. Miles Prince, MD, FRACP, FRCPA, Sandrine Macé, PhD, Laure Malinge, Franck Dubin, PharmD, Mony Morisse, MD, MSc and Kenneth C. Anderson, MD

ASH Abstract# 247: https://ash.confex.com/ash/2022/webprogram/Paper159710.html